Archivo para 2011

Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited, the leading pharmaceutical manufacturer in the southern hemisphere, has produced excellent results for the year ended 30 June 2011. GROUP PERFORMANCE: Revenue from continuing operations increased by 29% to R12.4 billion (R9,6 billion). Operating profit from continuing operations improved by 25% to R3.1 billion (R2.5 billion).…

Aspen increases revenue by 33 percent. Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited (Apn), Africa’s largest pharmaceutical manufacturer, has announced pleasing results for the interim period ended 31 December 2010. Group Performance: Headline earnings from continuing operations increased by 35 percent to R1.147 billion. Revenue from continuing operations rose by 33 percent to…

Nine questions – Stephen Saad Group Chief Executive, Aspen Pharmacare Holdings Limited Xolile Bhengu Thursday, 24 Feb 2011 2011 started off with finalising the Sigma Pharmaceuticals deal for R6,1bn. What does the acquisition mean for Aspen? The Sigma acquisition presents synergies for the extension of our existing branded products in Australia, with the addition of…

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that Irish-based Tibotec Pharmaceuticals has granted it a non-exclusive license to manufacture, market and distribute the Anti-retroviral (“ARV”) compound, rilpivirine hydrochloride (TMC278), pending approval of the molecule which could then be prescribed for patients commencing ARV treatment for the first time as well as for…

ASPEN ACQUIRES SIGMA’S PHARMACEUTICAL BUSINESS FOR R6,1 BILLION Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited (“Sigma”). The acquisition was approved following the extraordinary meeting of Sigma shareholders held on 14 January 2011. The…